BioCorRx (BICX) Debt to Equity (2016 - 2025)
Historic Debt to Equity for BioCorRx (BICX) over the last 11 years, with Q3 2025 value amounting to -$0.01.
- BioCorRx's Debt to Equity rose 9488.6% to -$0.01 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.01, marking a year-over-year increase of 9488.6%. This contributed to the annual value of -$0.01 for FY2024, which is 10572.68% down from last year.
- As of Q3 2025, BioCorRx's Debt to Equity stood at -$0.01, which was up 9488.6% from -$0.01 recorded in Q4 2024.
- BioCorRx's Debt to Equity's 5-year high stood at $0.1 during Q4 2023, with a 5-year trough of -$0.72 in Q1 2021.
- Over the past 5 years, BioCorRx's median Debt to Equity value was -$0.08 (recorded in 2024), while the average stood at -$0.21.
- In the last 5 years, BioCorRx's Debt to Equity crashed by 44164.87% in 2021 and then soared by 121487.33% in 2023.
- BioCorRx's Debt to Equity (Quarter) stood at -$0.02 in 2021, then surged by 40.8% to -$0.01 in 2022, then skyrocketed by 1214.87% to $0.1 in 2023, then tumbled by 105.73% to -$0.01 in 2024, then rose by 9.96% to -$0.01 in 2025.
- Its last three reported values are -$0.01 in Q3 2025, -$0.01 for Q4 2024, and -$0.1 during Q3 2024.